We are live on ! Find out more
QNCX icon

Quince Therapeutics
QNCX

37 hedge funds and large institutions have $12.5M invested in Quince Therapeutics in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

80% more capital invested

Capital invested by funds: $6.96M → $12.5M (+$5.55M)

16% more funds holding

Funds holding: 32 → 37 (+5)

0.02% more ownership

Funds ownership: 0.06% → 0.08% (+0.02%)

33% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 9

Holders
37
Holders Change
+5
Holders Change %
+15.63%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
6
Reduced
9
Closed
4
Calls
$96K
Puts
–
Net Calls
+$96K
Net Calls Change
+$21K

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$2.89M
2
Rockefeller Capital Management
Rockefeller Capital Management
New York
+$194K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$192K
4
USPCM
Union Square Park Capital Management
New York
+$138K
5
Millennium Management
Millennium Management
New York
+$126K

Top Sellers

Rank Fund Capital Flow
1
IC
IEQ Capital
California
-$420K
2
TCM
Tang Capital Management
California
-$245K
3
Renaissance Technologies
Renaissance Technologies
New York
-$137K
4
VF
Virtu Financial
New York
-$58K
5
Morgan Stanley
Morgan Stanley
New York
-$56.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
TSS
26
Two Sigma Securities
New York
$19.8K +$13.7K +60 New
NPT
27
Nixon Peabody Trust
Massachusetts
$18.4K – – –
Wells Fargo
28
Wells Fargo
California
$11.5K +$8K +35 New
Morgan Stanley
29
Morgan Stanley
New York
$7.1K -$56.2K -246 -92%
Bank of America
30
Bank of America
North Carolina
$4.79K +$229 +1 +7%
UBS Group
31
UBS Group
Switzerland
$4.7K +$2.29K +10 +250%
JP Morgan Chase
32
JP Morgan Chase
New York
$774 -$229 -1 -33%
JFG
33
JDM Financial Group
Texas
$561 – – –
PA
34
Parallel Advisors
California
$487 – – –
Osaic Holdings
35
Osaic Holdings
Arizona
$457 – – –
HC
36
Hurley Capital
New York
$200 – – –
HI
37
Harbour Investments
Wisconsin
$165 +$229 +1 New
SS
38
SBI Securities
Japan
$127 – – –
WIM
39
Westside Investment Management
California
$124 – – –
Barclays
40
Barclays
United Kingdom
$38 – – –
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$13 – – –
TCM
42
Tang Capital Management
California
– -$245K -922 Closed
VF
43
Virtu Financial
New York
– -$58K -217 Closed
HF
44
HRT Financial
New York
– -$19K -73 Closed
Group One Trading
45
Group One Trading
Illinois
– -$229 -1 Closed
Fidelity Investments
46
Fidelity Investments
Massachusetts
– -$67 – –
1
2

QNCX Hedge Fund Activity: Q2 2025 in Review

37 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q2 2025, worth a combined $12.5M — up 80% from $6.96M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new QNCX positions and 4 closed out — a net gain of 5 holders — while 6 added to existing stakes and 9 trimmed.

The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $2.89M. The largest seller was IEQ Capital, cutting an estimated $420K.

  • 37 institutional investors held Quince Therapeutics (QNCX) as of Q2 2025, up from 32 in Q1 2025.
  • Funds reported $12.5M of Quince Therapeutics stock for Q2 2025, up 80% quarter-over-quarter.
  • 9 funds opened new Quince Therapeutics positions in Q2 2025 and 4 closed out, a net change of +5 holders.
  • The largest Quince Therapeutics buyer in Q2 2025 was Nantahala Capital Management, an estimated $2.89M added.
  • The largest Quince Therapeutics seller in Q2 2025 was IEQ Capital, an estimated $420K sold.

Based on aggregated 13F filings for Q2 2025.